Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORMaT trial for Mycobacterium abscessus pulmonary disease
ISRCTN67303903Phase 2Recruiting
- Sponsor
- Nottingham University Hospitals
- Start
- Mar 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of amikacin, tigecycline, cefoxitin, imipenem, azithromycin and 9 more in Mycobacterium abscessus lung disease (8 arms), sponsored by Nottingham University Hospitals. Primary endpoints: Definition of MABS clearance at final outcome and Definition of tolerance. Started Mar 2020; status: recruiting.
02
Drugs
amikacintigecyclinecefoxitinimipenemazithromycin
03
Conditions
Mycobacterium abscessus lung disease
Beyond the preview
Go deeper on ISRCTN67303903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN67303903.